Tigo’s Newest MLPE Addition – TS4-A-2F the Most Cost-Effective Rapid Shutdown Solution – Announced at Solar Power International 2019
Tigo®, pioneer of the smart modular Flex MLPE & TS4 Platform, today announced its new TS4-A-2F (Fire Safety), the advanced retrofit/add-on rapid shutdown solution for two modules that provides smart PV module functionality. The TS4-A-2F is the newest, most partner adopted, and most cost-effective addition to Tigo’s advanced generation of flexible module-level power electronics in the TS4 Platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005637/en/
TS4-A-2F (Fire Safety) is the TS4 Platform’s newest advanced rapid shutdown solution for two modules up to 1000W and standard configuration of 1500V (Photo: Business Wire)
The UL-certified TS4-A-2F complies with NEC 2017 690.12 Rapid Shutdown specifications when installed with Tigo’s UL-certified RSS Transmitter or an inverter with Tigo's built-in RSS Transmitter. The unit’s powerline communication can be easily verified with Tigo’s RSS Signal Detector. System owners can ensure safety by upgrading existing PV systems or by adding these safety features to new installations. With this improved lightweight hardware, lower labor costs, and application for two modules, the TS4-A-2F is quickly becoming the most adopted rapid shutdown solution in the industry.
The highlights of TS4-A-2F include:
- Maximum Total Power is 1000W for two modules
- Maximum Current is 15A per input
- Available as 1500V UL
- UL-certified as NEC 2017 Rapid Shutdown Solution
- Snap to standard module frame or rack mounting
- Module-level deactivation with automatic or manual shutdown
- PV array enters rapid shutdown in event of AC grid loss
- Powerline communication (PLC) signaling
- Smaller unit dimensions with reduced weight per unit by 25%
- Reduced shipping costs with 33% more units per pallet
- Recessed mounting allows shipments of pre-assembled PV modules
- Improved heat dissipation with over-temperature and over-voltage protection
- Improved IP68 rating for greater outdoor exposure
- Download the datasheet here
Tigo’s TS4-A-2F will showcase at the Solar Power International (SPI) Exhibition Hall in Salt Lake City, Utah September 24 – 26, 2019. The UL-listed inverters with Tigo’s rapid shutdown solution showing at SPI include CPS (Booth 2201), Fronius (Booth 2019), GoodWe (Booth 2609), SolaX Power (Booth 719), Yaskawa Solectria Solar (Booth 2125), and more. The smart module manufacturers integrated with Tigo showing at SPI include GCL (Booth 1001), JA Solar (Booth 1219), Phono Solar (Booth 301), Suntech (Booth 211), Vikram Solar (4055), and more. To schedule an appointment or for an introduction to one of Tigo's manufacturing partners at SPI, contact sales@tigoenergy.com.
“Tigo’s TS4-A-2F is the most cost-effective rapid shutdown solution on the market today thanks to the accommodation of two modules,” says Zvi Alon, Chairman & CEO at Tigo. “Our inverter and module manufacturing partners see the value in this solution due to its readiness for new or existing systems of any size. Solar Power International is the perfect event to launch while we can collaborate with our many tier one partners to offer this UL-certified solution.”
Tigo’s TS4-A-2F is shipping with module manufacturers and distributors worldwide. This unit joins the other advanced retrofit/add-on units announced earlier this year: TS4-A-F (Fire Safety), TS4-A-O (Optimization), and TS4-A-O-Duo (Optimization per 2 modules). For price and delivery, consult your preferred PV module supplier, call Tigo at +1.408.402.0802 ext. 1, or email sales@tigoenergy.com.
About Tigo
Tigo is a Silicon Valley company founded in 2007 by a team of experienced technologists. Combining a unique systems-level approach with expertise in semiconductors, power electronics, and solar energy, the Tigo team developed the first-generation Smart Module Optimizer technology for the solar industry. Tigo's vision is to leverage integrated and retrofitted Flex MLPE and communications technology to drive the cost of solar electricity down. By partnering with tier 1 module and inverter manufacturers in the industry, Tigo is able to focus on its key innovation with the smartest TS4 modular platform and leverage the broader ecosystem. Tigo has operations in the USA, Europe, Latin America, Japan, China, Australia, and the Middle East. Visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005637/en/
Contact information
Media Contact for Tigo
Tiffany Douglass
408.402.0802 x 430
marketing@tigoenergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom